头孢洛扎-他唑巴坦对比美罗培南治疗ESBL及AmpC肠杆菌血流感染的MERINO-3试验方案
BACKGROUND: Extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales are common causes of bloodstream infection. ESBL-producing bacteria are typically resistant to third-generation cephalosporins and result in a sizeable economic and public health burden.…
要点
- 比较头孢洛扎-他唑巴坦与美罗培南对ESBL/AmpC肠杆菌血流感染的疗效。
- 设计为非劣效性试验,非劣效界值5%,假设两组30天死亡率均为5%。
核心结论
- 头孢洛扎-他唑巴坦是否在ESBL或AmpC肠杆菌血流感染中不劣于美罗培南,将由本试验验证。
研究设计与样本
- 多中心、平行组、开放标签、非劣效性随机对照试验。
- 入组成人ESBL或AmpC肠杆菌血流感染患者,最多40个中心、六个国家参与。
- 1:1随机接受头孢洛扎-他唑巴坦3 g或美罗培南1 g,均每8小时一次。
- 目标600例可评估主要结局,把握度80%,非劣效界值5%。
关键数值与推荐
- 主要终点分析预计需600例,假设两组30天死亡率均为5%,非劣效界值5%。
- 目标病原为三代头孢不敏感的大肠埃希菌、克雷伯菌属或肠杆菌属、弗氏柠檬酸杆菌、摩根摩根菌、普罗威登斯菌属或粘质沙雷菌。
- 确定性治疗最短5天、最长14天,总疗程由治疗医生决定。
- 次要结局包括14天全因死亡率、第5天临床与微生物学成功、功能性菌血症评分等。
临床怎么用
- 若结果支持非劣效,头孢洛扎-他唑巴坦可作为限制碳青霉烯类使用的备选方案。
- 试验采用固定剂量每8小时一次方案,疗程由临床医生在5至14天范围内决定。
局限性
- 开放标签设计可能引入实施与结局评估偏倚。
- 样本量由预设的头孢洛扎-他唑巴坦供应量决定,而非完全按效应量推算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales are common causes of bloodstream infection. ESBL-producing bacteria are typically resistant to third-generation cephalosporins and result in a sizeable economic and public health burden. AmpC-producing Enterobacterales may develop third-generation cephalosporin resistance through enzyme hyper-expression. In no observational study has the outcome of treatment of these infections been surpassed by carbapenems. Widespread use of carbapenems may drive the development of carbapenem-resistant Gram-negative bacilli. METHODS: This study will use a multicentre, parallel group open-label non-inferiority trial design comparing ceftolozane-tazobactam and meropenem in adult patients with bloodstream infection caused by ESBL or AmpC-producing Enterobacterales. Trial recruitment will occur in up to 40 sites in six countries (Australia, Singapore, Italy, Spain, Saudi Arabia and Lebanon). The sample size is determined by a predefined quantity of ceftolozane-tazobactam to be supplied by Merck, Sharpe and Dohme (MSD). We anticipate that a trial with 600 patients contributing to the primary outcome analysis would have 80% power to declare non-inferiority with a 5% non-inferiority margin, assuming a 30-day mortality of 5% in both randomised groups. Once randomised, definitive treatment will be for a minimum of 5 days and a maximum of 14 days with the total duration determined by treating clinicians. Data describing demographic information, risk factors, concomitant antibiotics, illness scores, microbiology, multidrug-resistant organism screening, discharge and mortality will be collected. DISCUSSION: Participants will have bloodstream infection due to third-generation cephalosporin non-susceptible E. coli and Klebsiella spp. or Enterobacter spp., Citrobacter freundii, Morganella morganii, Providencia spp. or Serratia marcescens. They will be randomised 1:1 to ceftolozane-tazobactam 3 g versus meropenem 1 g, both every 8 h. Secondary outcomes will be a comparison of 14-day all-cause mortality, clinical and microbiological success at day 5, functional bacteraemia score, microbiological relapse, new bloodstream infection, length of hospital stay, serious adverse events, C. difficile infection, multidrug-resistant organism colonisation. The estimated trial completion date is December 2024. TRIAL REGISTRATION: The MERINO-3 trial is registered under the US National Institute of Health ClinicalTrials.gov register, reference number: NCT04238390 . Registered on 23 January 2020.
引用
- Stewart AG, Harris PNA, Chatfield MD, et al. Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial. Trials. 2021. PMID: 33888139. doi:10.1186/s13063-021-05206-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。